1.Chrousos GP. The Hypothalamic-Pituitary-Adrenal axis and the immune/inflammatory reaction. New England Journal Medicine 1995; 332: 1351-1362 .

2.Johnson HM. Neuroendocrine peptide hormone regulation of immunity. Neuroimmunoendocrinology, edn 2nd , pp. 49-83, Eds Karger, 1992.

3.Mastorakos G. and Ilias I. The emerging role of peripheral corticotrophin-releasing hormone (CRH). Journal of Endocrinology Investigations 2002, 26 364-371.

4.Chrousos G. P and Gold P. W.The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. Journal of American Medical Association 1992 2671244-1252

5.Rivier C., Brownstein M., Spiess J., Rivier J and Vale W. In vivo corticotrophin-releasing factor-induced secretion of adrenocorticotropin, b-endorphin and corticosterone. Endocrinology 1982 110 272-278

6.Vale W, Rivier C, Brown MR, Spiess J, Koob G, Swanson L, Bilezikjian L, Bloom F, and Rivier J. Chemical and biological characterization of corticotrophin releasing factor. Recent Progress in Hormone Research. 1983 39 245-270

7.Spiess J, Rivier J, Rivier C and Vale W. Primary structure of corticotrophin-releasing factor from ovine Hypothalamus. Proceedings of the National. Academy of Sciences of the United States of America 1981 78 6517-6521.

8.Donaldson CJ, Sutton SW, Perrin MH, Corrigan AZ, Lewis KA, Rivier JE, Vaughan JM and Vale WW.. Cloning and characterization of human urocortin. Endocrinology 1996 137 2167-2170

9.Shibahara S, Morimoto Y, Furutani Y, Notake M, Takahashi H, Shimizu S, Horikawa S and Numa S. Isolation and sequence analysis of the human corticotrophin-releasing factor precursor gene. The EMBO Journal 1983 2 775-779

10.Swanson LW, Sawchenko PE, Rivier J and Vale W.W. Organization of ovine corticotrophin-releasing factor immunoreactive cells and fibers in the rat brain: An immunohistochemical study. Neuroendocrinology 1983, 36165-186.

11.Baker C, Richards LJ, Dayan CM and Jessop DS. CRH immunoreactivity in human T and B cells and macrophages: colocalization with AVP. Journal of Neuroendocrinology 2003 15 1070-1074

12.Sawchenko PE, Swanson LW and Vale WW. Corticotropin-releasing factors: Coexpression with distinct subsets of oxytocin-, vasopressin-, and neurotensin-immunoreactive neurons in the hypothalamus of the male rat. Journal of Neuroscience 1984 4 1118-1129.

13.Schurmeyer TH, Avgerinos PC, Gold PW, Gallucci WT, Tomai TP, Cutler GB Jr, Loriaux DL and Chrousos GP. Human corticotrophin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenicotropin and cortisol secretion. Journal of Clinical Endocrinology and Metabolism. 1984 59 1103-1108

14.Conaglen JV, Donald RA, Espiner EA, Livesey JH and Nicholls MG. The effect of ovine corticotrophin-releasing factor on catecholamine, vasopressin and aldosterone secretion in normal man. Journal of Clinical Endocrinology and Metabolism. 1984 58 463-466

15.Pavlov EP, Harman SM, Chrousos GP, Loriaux DL and Blackman MR.. Responses of plasma adrenocorticotropin, cortisol and dehydroepiandrosterone to ovine corticotropin-releasing hormone in healthy aging men. Journal of Clinical Endocrinology and Metabolism. 1986 62 767-772

16.Grino M., Chrousos G.P. and Margioris A.N. The corticotrophin releasing hormone gene is expressed in human placenta. Biochemical and Biophysical Research Communications. 1987 148 1208-1214

17.Mastorakos G, Scopa CD, Kao LC, Vryonidou A, Friedman TC, Kattis D, Phenekos C, Rabin D and Chrousos GP. Presence of immunoreactive corticotrophin releasing hormone in human endometrium. Journal of Clinical Endocrinology and Metabolism 1996 81 1046-1050

18.Ferrari A., Petraglia F and Gurpide E. Corticotropin releasing factor decidualizes human endometrial stromal cells in vitro. Interaction with progestin. The Journal of Steroid Biochemistry and Molecular Biology 1995 54 251-255

19.Petraglia F, Tabanelli S, Galassi MC, Garuti GC, Mancini AC, Genazzani AR and Gurpide E. Human deciduas and in vitro decidualized endometrial stromal cells at term contain immunoreactive corticotrophin-releasing factor (CRF) and CRF messenger ribonucleic acid. Journal of Clinical Endocrinology and Metabolism. 1992 74 1427-1431

20.Fabbri A, Tinajero JC and Dufau ML. Corticotropin-releasing factor is produced by rat Leydig cells and has a major local antireproductive role in the testis. Endocrinology 1990 127 1541-1543

21.Baigent S.M. Peripheral corticotrophin-releasing hormone and urocortin in the control of the immune response. Elsevier peptides ch, 22 pp 809-820, 2001.

22.Mastorakos G, Scopa CD, Friedman TC, Melachrinou M, Merino MJ and Chrousos GP. Presence of immunoreactive corticotrophin-releasing hormone (CRH) in thyroid lesions. The American Journal of Pathology. 1994 145 1159-1167

23.Mastorakos G, Bouzas EA, Silver PB, Sartani G, Friedman TC, Chan CC, Caspi RR and Chrousos GP. Immune corticotrophin-releasing hormone is present in the eyes of and promotes experimental autoimmune uveoretinitis in rodents. Endocrinology 1995 136 4650-4658

24.Zhao J and Karalis KP. Regulation of NF-kB by corticotrophin-releasing hormone in mouse thymocytes. Molecular Endocrinology. 2002 16 2561-2570

25.Zbytek B, Pfeffer LM and Slominski AT. Corticotropin-releasing hormone stimulates NF-kB in human epidermal keratinocytes. Journal of Endocrinology 2004 181 R1-R7

26.Karalis K, Sano H, Redwine J, Listwak S, Wilder RL and Chrousos GP. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991 254 421-423

27. Linton EA, Wolfe CD, Behan DP and Lowry PJ. A specific carrier substance for human corticotrophin releasing factor in late gestational maternal plasma which could mask the ACTH-releasing activity. Clinical Endocrinology (Oxf) 1988, 28 315-324.

28.Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. Journal of Endocrinology 2005 184 11-28

29.Perrin M.H. and Vale W.W. 1999 Corticotropin releasing factor receptors and their ligand family. Annals NewYork Academy of Science 1999 885 312-328

30.Agelaki S, Tsatsanis C, Gravanis A and Margioris AN. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infection and immunity 2002 70 6068-6074

31.Mastorakos G., Webster E.L., Friedman T.C., Chrousos G.P. Immunoreactive corticotrophin releasing hormone (CRH) and its binding sites in the rat ovary. J. Clin. Invest. 1993, 92:961-968

32.Mastorakos G, Scopa CD, Vryonidou A, Friedman TC, Kattis D, Phenekos C, Merino MJ and Chrousos GP. Presence of immunoreactive corticotrophin releasing hormone (CRH) in normal and polycystic human ovaries. Journal of Clinical Endocrinology and Metabolism 1994 79 1191-1197

33.Slominski A, Wortsman J, Pisarchik A, Zbytek B, Linton EA, Mazurkiewicz JE and Wei ET. Cutaneous expression of corticotrophin-releasing hormone (CRH), urocortin, and CRH receptors. The FASEB Journal. 2001 15 1678-1693

34.Chalmers DT, Lovenberg TW, Grigoriadis DE, Behan DP and DeSouza EB. Corticotropin releasing factor receptors: from molecular biology to drug design. Trends in Pharmacological Sciences 1996 17 166-172

35.Mastorakos G, Scopa CD, Kao LC, Vryonidou A, Friedman TC, Kattis D, Phenekos C, Rabin D and Chrousos GP. Presence of immunoreactive corticotrophin releasing hormone in human endometrium. Journal of Clinical Endocrinology and Metabolism 1996 81 1046-1050

36.Chen R, Lewis KA, Perrin MH and Vale WW. Expression cloning of a human corticotrophin releasing factor receptor. Proceedings of the National. Academy of Sciences of the United States of America 1993 90 8967-8971.

37.Hauger RL and Aguilera G. Regulation of pituitary corticotrophin releasing hormone (CRH) receptors by CRH: interaction with vasopressin. Endocrinology 1993 1331708-1714.

38.Zhao J and Karalis KP. Regulation of NF-κB by CRH in mouse thymocytes. Molecular Endocrinology 2002 16 2561-2570.

39.Rossant CJ, RD Pinnock, J Hughes, MD Hall and S McNulty. Corticotropin releasing factor type 1 and type 2 a receptors regulate phosphorylation of calcium/cyclic adenosine 3’, 5’-monophosphate response element-binding protein and activation of p42/p44 mitogen activated protein kinase. Endocrinology 1999 140 1525.

40.Sananbenesi F, Fischer A, Schrick C, Spiess J, Radulovic J . Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotrophin releasing factor receptor 2: a possible link between stress and fear memory.The Journal of Neuroscience 2003 23 11436.

41.Zhao Jie, Karalis P. Katia .Regulation of nuclear factor-κ B by coricotropin releasing hormone in mouse thymocytes. Molecular Endocrinology 2002 16(11):2561-2570

42.Wright HV, Bailey D, Kashyap M, Kepley CL, Drutskaya MS, Nedospasov SA and Ryan JJ. IL-3 mediated TNF production is necessary for mast cell development. The Journal of Immunology 2006 176 2114-2121

43.Mann-Chandler MN, Kashyap M, Wright HV, Norozian F, Barnstein BO, Gingras S, Parganas E and Ryan JJ. IFN-γ induces apoptosis in developing mast cells. The Journal of Immunology 2005 175 3000-3005

44.Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL and Theoharides TC. Human mast cells express corticotropin releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor .The Journal of Immunology 2005 174 7665-7675

45.Elenkov IJ, Papanicolaou DA, Wilder RL and Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proceedings of the Association of American Physicians. 1996 108 374-381.

46. Blotta MH, DeKruyff RH and Umetsu DT. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. Journal of Immunology 1997 158 5589-5595.

47.Ramierez F, Fowell DJ, Puklavec M, Simmonds S and Mason D. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. Journal of Immunology 1996 156:2406-2412.

48.Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, Self C and Sinigaglia F. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. Journal of Clinical Investigations 1997 100 1513-1519.

49.Elenkov IJ, Webster EL, Torpy DJ and Chrousos GP. Stress, corticotropin releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Annals of NewYork Academy of Science1999 876 1-13.

50.Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993; 77: 1690-1694.

51.Mastorakos G, Weber JS, Magiakou MA, Gunn H and Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. Journal of Clinical Endocrinology and Metabolism 1994 79 934-939.

52.Silverman ES, Breault DT, Vallone J, Subramanian S, Yilmaz AD, Mathew S, Subramaniam V, Tantisira K, Pacak K, Weiss ST and Majzoub JA. Corticotropin-releasing hormone deficiency increases allergen-induced airway inflammation in a mouse model of asthma. Journal of Allergy and Clinical Immunology. 2004 114 747-754.

53.Johnson EO, Skopouli FN and Moutsopoulos HM. Neuroendocrine manifestations in Sjogren's syndrome. Rheum Diseases Clinics of North America. 2000 26 927-949.

54.Porter N, Beynon HL and Randeva H.S. Endocrine and reproductive manifestations of sarcoidosis Q J Med 2003 96 553–561.55.

55.Kavelaars A, Berkenbosch F, Croiset G, Ballieux RE and Heijnen CJ. Induction of beta-endorphin secretion by lymphocytes after subcutaneous administration of corticotropin-releasing hormone. Endocrinology 1990 126 759-764.

56. Kohno M., KawahitoY, Tsubouchi Y, Hashiramoto A.,Yamada R, Inoue KI, Kusaka Y, Kubo T, Elenkov IJ, Chrousos GP, Kondo M, Sano H. Urocortin Expression in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis: Relation to Inflammatory Activity. Journal of Clinical Endocrinology and Metabolism 2001 86 4344–4352.

57. Crofford LJ, Sano H, Karalis K, Friedman TC, Epps HR, Remmers EF, Mathern P, Chrousos GP and Wilder RL.. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arhtritis and osteoarthritis. The Journal of Immunology 1993 151 1-10.

58. Mastorakos G, Silver PB, Bouzas EA, Caspi RR, Chan CC and Chrousos GP. Immunoreactive corticotropin releasing hormone in experimental autoimmune uveoretinitis in rodents. Endocrinology. 1995 136 4650-8.

59. Poulaki V, Mitsiades N, Mastorakos G, Caspi RR, Chrousos GP and Bouzas E. Fas/fas ligand-associated apoptosis in experimental autoimmune uveoretinitis in rodents: role of proinflammatory corticotropin-releasing hormone. Experimental Eye Research 2001 72 623-629.

60. Karalis K, Mastorakos G, Chrousos GP and Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. Journal of Clinical Investigations 1994 93 2000-2006

61. Karalis K, Mastorakos G, Sano H, Wilder RL and Chrousos GP. Somatostatin may participate in the anti-inflammatory actions of glucocorticoids. Endocrinology 1995 136 4133-4138.

62. Benou C, Wang Y, Imitola J, VanVlerken L, Chandras C, Karalis KP and Khoury SJ. Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. Journal of Immunology 2005 174 5407-13.

63. Ian M.R. Wright. Corticotropin-releasing hormone causes vasodilation in human skin via mast cell-dependent pathways. Journal of Clinical Endocrinology and metabolism 2003 88 5427-5432

64. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K, Madhappan B, Boucher W, Christodoulou S, Athanassiou A and Theocharides TC. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 2004 145 43-48.

65. Anton MA, Gay J, Mykoniatis A, Pan A, O’Brien M, Brown D, Karalis K and Pothoulakis C. Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proceedings of the National. Academy of Sciences of the United States of America 2004 101 8503–8508

66. Crofford LJ, Sano H, Karalis K, Webster EL, Goldmuntz EA, Chrousos GP and Wilder RL. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. Journal of Clinical Investigation 1992 90 2555-2564.

67. Kalantaridou SN, Makrigiannakis A, Mastorakos G and Chrousos GP. Roles of reproductive corticotropin-releasing hormone. Annals of NewYork Academy of Science 2003 99 7125-135.

68. Mastorakos G, Ghizzoni L, Webster EL and Chrousos GP.Autocrine-paracrine role of ovarian corticotropin- releasing hormone Annals of New York Academy of Science 1997 816, 27-41.

69. Asakura H, Zwain IH, Yen SSC. (1997) Expression of genes encoding corticotropin-releasing factor (CRF), type 1 CRF receptor, and CRF-binding protein and localization of the gene products in the human ovary. J Clin Endocrinol Metab. 82:2720–2725.

70. Makrigiannakis A, Zoumakis E, Margioris AN, Theodoropoulos P, Stournaras C and Gravanis A. The corticotropin-releasing hormone in normal and tumoral epithelial cells of human endometrium. Journal of Clinical Endocrinology and Metabolism. 1995a 80 185-189.

71. Makrigiannakis A, Zoumakis E, Margioris AN, Stournaras C, Chrousos G.P and Gravanis A. Corticotropin-releasing hormone (CRH) is expressed at the implantation sites of early pregnant rat uterus. Life Sciences 1995b 57 1869-1875

72. Di Blasio A M, Giraldi P F, Vigano P, Petraglia F, Vignali M and Cavagnini F. Expression of Corticotropin-releasing hormone and its R1 receptor in human endometrial stromal cells. Journal of Clinical Endocrinology and Metabolism.1997 82 1594-1597.

73. Grammatopoulos D and Hillhouse EW. Solubilization and biochemical characterization of the human myometrial corticotrophin-releasing hormone receptor. Molecular Cellular Endocrinology 1998 138 185-198.

74. Grammatopoulos D K, Dai Y, Randeva H S, Levine M, Karteris E., Easton A and Hillhouse E W. A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Molecular Endocrinology 1999 13,2189-2202.

75. Clifton V L, Telfer J F, Thompson A J, Cameron I T, Teoh T G, Lye S J and Challis J R.Corticotropin-releasing hormone and proopiomelanocortin-derived peptides are present in human myometrium. Journal of Clinical Endocrinology and Metabolism.1998 83 3716-3721.

76. Linton E A, Woodman J R, Asboth B P, Plested C P and Lopez Bernal A. Corticotropin-releasing hormone : its potential for a role in human myometrium.Experimental Physiology(Uterine Contractility Symposium) 2001 86.2 273-281.

77.Riley S, Walton J, Herlick J and Challis J. The localization and distribution of corticotropin- releasing hormone in the placenta and fetal membranes throughout gestation. Journal of Clinical Endocrinology and Metabolism.1991 72 1001-1007.

78. Gravanis A, Makrigiannakis A, Zoumakis E and Margioris A. Endometrial and myometrial corticotropin- releasing hormone (CRH): its regulation and possible roles.Peptides 2001 22 785-793.

79. Hillhouse E W and Grammatopoulos D K. Role of stress peptides during human pregnancy and labour. Reproduction 2002 124 323-329.

80. Grammatopoulos D K, Dai Y, Randeva H S, Levine M, Karteris E., Easton A and Hillhouse E W. A novel spliced variant of the type 1 corticotropin-releasing hormone receptor with a deletion in the seventh transmembrane domain present in the human pregnant term myometrium and fetal membranes. Molecular Endocrinology 1999 13,2189-2202.

81.Karteris, E., Grammatopoulos, D., Dai, Y., Olah, K. B., Ghobara, T. B., Easton, A., Hillhouse, E. W. (1998) The human placenta and fetal membranes express the corticotropin-releasing hormone receptor 1 (CRH-1 ) and the CRH-C variant receptor. J. Clin. Endocrinol. Metab. 83,1376-1379.

82.Karteris E, Grammatopoulos D, Randeva HS and Hillhouse E W.The role of corticotropin-releasing hormone receptors in placenta and fetal membranes during human pregnancy .Molecular Genetics and Metabolism 2001 72 287-296.

83.Calogero AE, Burrello N, Negri-Cesi P, Papale L, Palumbo MA, Cianci A, Sanfilippo S and D'Agata R. Effects of corticotropin-releasing hormone on ovarian estrogen production in vitro. Endocrinology. 1996 137 4161–4166.

84.Ghizzoni L, Mastorakos G, Vottero A, Barreca A, Furlini M, Cesarone A, Ferrari B, Chrousos GP and Bernasconi S. Corticotropin-releasing hormone (CRH) inhibits steroid biosynthesis by cultured human granulosa-lutein cells in a CRH and interleukin-1 receptor-mediated fashion. Endocrinology 1997 138 4806–4811

85. Erden HF, Zwain IH, Asakura H, Yen SSC. Corticotropin-releasing factor inhibits luteinizing hormone-stimulated P450c17 gene expression and androgen production by isolated thecal cells of human ovarian follicles. Journal of Clinical Endocrinology and Metabolism. 1998 83 448–452

86.Muramatsu Y, Sugino N, Suzuki T, Totsune K, Takahashi K, Tashiro A, Hongo M, Oki Y and Sasano H. Urocortin and corticotropin-releasing factor receptor expression in normal cycling human ovaries. Journal of Clinical Endocrinology and Metabolism. 2001 86 1362–1369.

87. Gravanis A, Makrigiannakis A, Chatzaki A, Zoumakis E, Tsatsanis C and Margioris A.N. Stress neuropeptides in the human endometrium: Paracrine effects on cell differentiation and apoptosis. Hormones 2002 1 139-148.

88. Zoumakis E, Margioris AN, Stournaras C, Dermitzaki E, Angelakis E, Makrigiannakis A, Koumantakis E and Gravanis A. Corticotropin-releasing hormone (CRH) interacts with inflammatory prostaglandins and interleukins and affects decidualization of human endometrial stroma. Molecular Human Reproduction 2000 6 344-351

89. Makrigiannakis A, Zoumakis E , Κalantaridou S, Chrousos G P.Endometrial and placental CRH as regulators of human embryo implantation.Journal of Reproductive Immunology.2004 62 53-59.

90. Runic R, Lockwood CJ, Ma Y, Dispaquale B and Guller S. Expression of Fas ligand by human cytotrophoblasts: implication in implantation and fetal survival. The Journal of Clinical Endocrinology and Metabolism 1996 81 3119-3122

91. Makrigiannakis A., Zoumakis E., Kalantaridou S., Coutifaris C., Margioris A., Coulos G., Rice K.C., Gravanis A. and Chrousos G.P. Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nature Immunology . 2001 2 1018-1024.

92.Μastorakos G and Ilias I.Maternal hypothalamic-pituitary -adrenal axis in pregnancy and postpartum period.Annals New York Academy of Science 2003 997, 136-149.

93.Sirianni R, Mayhew B A, Carr B R, Parker C R and Rainey W E. Corticotropin-releasing hormone (CRH) and Urocortin act through type 1 CRH receptors to stimulate dehydroepiandrosterone sulfate production in human fetal adrenal cells. Journal of Clinical Endocrinology and Metabolism 2005 90 5393-5400.

94. Karteris E , Vatish M, Hillhouse E W and Grammatopoulos D K. Preeclampsia is associated with impaired regulation of the placental nitric oxide-cyclic guanosine monophosphate pathway by corticotropin-releasing hormone(CRH) and CRH-related peptides. Journal of Clinical Endocrinology and Metabolism 2005 90 3680-3687.

95. Herrmann TS, Siega-Riz A M, Hobel C J, Aurora C and Dunkel-Schetter C. Prolonged periods without food intake during pregnancy increase risk for elevated maternal corticotropin-releasing hormone concentrations. American Journal of Obstetrics and Gynaecology2001 185 403-413.

96.Rosenberg L, Palmer JR, Wise LA, Horton N J and Corwin M J.Perceptions of racial discrimination and the risk of preterm birth. Epidemiology 2002 13 646-652.

97.Rich-Edwards J W and Grizzard T A. Psychosocial stress and neuroendocrine mechanisms in preterm delivery. American Journal of Obstetrics and Gynaecology 2005 192 S30-35.

98.Mastorakos G. and Ilias I. Relationship between IL-6 and hypothalamic-pituitary-adrenal axis hormones in rheumatoid arthritis. Z.Rheumatol. 2000 59 75-79.

99.Webster, E.L.., Lewis, D.B., Torpy, D.J., Zachman, E.K., Rice, K.C., Chrousos, G.P.(1996). In vivo and in vitro Characterization of Antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: Suppression of Pituitary ACTH Release and Peripheral inflammation. Endocrinology 137,5747-5750.

100.Webster, E.L.(2002). Corticotropin- releasing hormone (CRH) antagonist attenuates adjuvant-induced arthritis: role of CRH in peripheral inflammation.J.Rheumatol.29,1252-1261.

101.Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E and Chrousos G. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability; a possible explanation for its proinflammatory effects. Endocrinology 1998 139 403-413.

102.Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Conolly R and Theoharides T.C. Corticotropin-releasing hormone and brain mast cells regulate BBB permeability induced by acute stress. Journal of Pharmacological Experimental Therapeutics 2002 303 1061-1066.

103.Kawahito Y, Sano H, Mukai S, Asai K, Kimura S, Yamamura Y, Kato H, Chrousos G.P., Wilder R.L and Kondo M. Corticotropin-releasing hormone in colonic mucosa in patients with ulcerative colitis. Gut 1995 37 544 -551.

104.Gravanis A and Margioris A. The Corticotropin-Releasing Factor (CRF) Family of Neuropeptides in Inflammation: Potential Therapeutic Applications. Bioactive Peptides for Immune Disease Therapy. Current Medicinal Chemistry 2005 13 1467.

105.Chan E.C. Corticotropin-releasing hormone type 1 receptor antagonist delays parturition in sheep. Endocrinology 1998 139 3357-3360.